基本信息
views: 5
![](https://originalfileserver.aminer.cn/sys/aminer/icon/show-trajectory.png)
Bio
The lab of Mark Goodarzi, MD, PhD, seeks to identify genetic factors underlying conditions related to insulin resistance and the metabolic syndrome, using a population genetic approach. A major focus area is elucidation of the genetic determinants of insulin clearance, via candidate gene and genome-wide association analyses. Other areas of interest include insulin resistance and atherosclerosis in Hispanics and the polycystic ovary syndrome. Pharmacogenetic studies are focused on the glycemic response to statins. Another research effort is an NIH-funded study examining the ability of GLP-1 agonists to prevent diabetes in Hispanic women with prediabetes, where insulin-related traits are measured by detailed physiologic phenotyping techniques. As the co-convener of the CHARGE (Cohorts for Heart and Aging Research in Genomic Epidemiology) Glycemia-Diabetes Working Group, Dr. Goodarzi also leads an international consortium that assembled over 20 cohorts (comprising over 100,000 individuals) for the study of common and rare variants that contribute to glucose homeostasis and type 2 diabetes. Dr. Goodarzi also leads the Type 3c Diabetes Working Group within the U01-funded Consortium for the Study of Chronic Pancreatitis, Diabetes, and Pancreatic Cancer (CPDPC), where he seeks to elucidate the pathophysiology of pancreatogenic diabetes using genetic and physiologic approaches. Dr. Goodarzi also leads the Microbiome and Insulin Longitudinal Evaluation Study (MILES), which is the first prospective study examining the effect of the gut microbiome and diet on insulin resistance, insulin sensitivity, and insulin clearance, to establish the causal role of gut microbes in the development of diabetes.
Research Interests
Papers共 370 篇Author StatisticsCo-AuthorSimilar Experts
By YearBy Citation主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
DIABETESno. 3 (2024): 385-390
Shuke Xiao,Veronica L. Li,Xuchao Lyu, Xudong Chen,Wei Wei,Fahim Abbasi,Joshua W. Knowles,Alan Sheng-Hwa Tung,Shuliang Deng, Gaurav Tiwari,Xu Shi,Shuning Zheng,
Nature Metabolismno. 4 (2024): 1-11
Nature reviews. Disease primersno. 1 (2024): 27-27
Loes M.E. Moolhuijsen,Jia Zhu,Benjamin H. Mullin,Natàlia Pujol-Gualdo,Ky’Era V. Actkins,Jasmine A. Mack, Hridya Rao,Bhavi Trivedi,Katherine A. Kentistou,Yajie Zhao, David Westergard,Jaakko S. Tyrmi,
crossref(2024)
Jingzhong Ding,Anh Tram Nguyen,Kurt Lohman, Michael T Hensley, Daniel Parker,Li Hou,Jackson Taylor,Deepak Voora,Janet K Sawyer,Elena Boudyguina,Michael P Bancks,Alain Bertoni,
The Journal of clinical investigationno. 10 (2024)
Zhenqi Zhou,Alice Ma,Timothy M. Moore,Dane M. Wolf, Nicole Yang, Peter Tran,Mayuko Segawa,Alexander R. Strumwasser, Wenjuan Ren, Kai Fu,Jonathan Wanagat,Alexander M. van der Bliek,
SCIENCE ADVANCESno. 14 (2024): eadl0389-eadl0389
Soo Heon Kwak, Ryan B Hernandez-Cancela,Daniel A DiCorpo,David E Condon,Jordi Merino,Peitao Wu,Jennifer A Brody,Jie Yao,Xiuqing Guo,Fariba Ahmadizar,Mariah Meyer,Murat Sincan,
Nature Reviews Disease Primersno. 1 (2024)
COMMUNICATIONS MEDICINEno. 1 (2024): 66-66
Load More
Author Statistics
Co-Author
Co-Institution
D-Core
- 合作者
- 学生
- 导师
Data Disclaimer
The page data are from open Internet sources, cooperative publishers and automatic analysis results through AI technology. We do not make any commitments and guarantees for the validity, accuracy, correctness, reliability, completeness and timeliness of the page data. If you have any questions, please contact us by email: report@aminer.cn